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Abstract
               The implantable cardioverter defibrillator has achieved increasing acceptance in 
paediatric cardiologic practice. Concurrent with technological advances which have made the 
devices more versatile, easier to implant and to program, there has been a fundamental 
breakthrough in our understanding of genetic and inherited arrhythmia syndromes in the last 
decade. This in turn has led to investigations into risk stratification, with the aim of choosing 
high risk candidates for timely device therapy. The second group of young patients with a risk of 
sudden death are those who have had a previous repair of a structural heart defect. Given that 
sudden arrhythmic death is the commonest cause of mortality in this population, it behoves the 
practising paediatric cardiologist to be aware of the current recommendations for device 
implantation in this population. In this manuscript, we summarise the current state of our 
understanding of the risk factors for sudden death, and identify possible candidates for ICD 
implantation. 
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Introduction
            It is well recognised that implantable cardioversion / defibrillation devices (ICDs), can be 
potentially lifesaving in children at risk of arrhythmic sudden death. In a wide variety of settings 
however, the appropriate selection criteria for ICD implantation at a young age remain unclear. 
This has resulted both in device over-utilisation in certain disease categories, and potential 
under-utilisation in others. We shall attempt to provide some guidelines on the appropriate 
indications, and the potential benefits and risks of ICD implantation in this population.
            The role of ICDs may broadly be considered under two headings: devices for primary 
electrical disease, and devices to prevent sudden arrhythmic death in patients who have 
previously undergone surgical repair for congenital heart defects.                           
Primary Electrical Disease                                                                                         
            In 1996, Maron et al provided autopsy data on the causes of sudden unexpected death in 
134 young athletes aged <40 years. Approximately 45% of the deaths could be attributed to 
potentially inherited diseases1. Two other studies looking at the causes of sudden death in young 
individuals (non-athletes) reached roughly similar conclusions2,3. In recent years, rapid advances 
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in our understanding of the function of cardiac cellular ion channels, their role in generating and 
maintaining the normal cardiac action potential, and the arrhythmogenic effects of impaired/ 
altered function resulting from mutations affecting the genes which regulate channel structure 
and function, have all led to a surge of interest in ion channel disease, or the channelopathies. 
Mutations in different genes can cause a range of congenital arrhythmia syndromes. These 
mutations can produce diverse functional effects in utero, and clinical overlap into different 
disease phenotypes resulting from a single gene mutation, particularly for sodium channel gene 
mutations, are recognised. The clinical features of a genetic mutation affecting one of the ion 
channel proteins can vary not only according to genotype, but also by the specific mutation. 
The   congenital   long   QT   syndrome                                                                  
            The disease which has been recognised the longest, and consequently has received the 
most attention, is the congenital long QT syndrome. The congenital LQTS is estimated to affect 
approximately 1 in 5000 persons, and the first chromomal defects causing LQTS were identified 
in 19954,5. Eight genotypes (over 400 mutations) are known to date, seven of them being ion 
channel gene mutations, and one of them (LQT4) a structual anchoring protein mutation. Beta 
blockers are the mainstay of management, although occasionally other drugs may be tried for 
specific genotypes. Left cardiac sympathetic denervation (LCSD) may be tried in patients with 
severe clinical phenotype associated with QTc>500. Although not completely protective, in 
responders (those in whom the QTc decreases to <500 within 6 months of LCSD) a significant 
reduction in the incidence of syncope and aborted sudden death have been reported6.              
Indications   for   ICD   in   LQTS                                                          
               Class I indications for ICD in congenital LQTS include resuscitated ventricular 
fibrillation or aborted sudden death. Additional clinical states in which ICDs may be considered 
include a family history of sudden death in a first degree relative in conjunction with a QTc 
>500, and recurrent syncope despite appropriate pharamacologic compliance with beta-blocker 
therapy. Attempts at more sophisticated risk stratification based on genotype, sex and QTc have 
generally not been well accepted in paediatric practice, as the overlap between the different risk 
categories is too large. It is important however to recognise that LQT1, LQT2 and LQT3 
together account for approximately 70% of all patients with LQTS, and exhibit specific 
genotype-phenotype  relationships.   Thus  arrhythmic  events   in  LQT1  are  most  commonly 
triggered by exercise or emotional upset (sympathetic overdrive); clinical events in LQT2 are 
most commonly triggered by sudden emotional upset (including auditory stimuli), while LQT3 
related events occur predominantly at rest7. Appropriate steps need therefore to be taken to avoid 
triggering events. Exercise testing may be helpful in LQT1, to confirm non-shortening of the QT 
interval with exercise, as part of the risk-stratification algorithm.                             
            Recent interest has focused on mutation-site specific differences in arrhythmic risk and in 
sensitivity to sympathetic stimulation in LQT1. Transmembrane domain mutations have been 
shown to cause a greater prolongation of various measured repolarization parameters, and to be 
associated with a greater clinical risk of arrhythmia when compared to C-terminal mutations8. 
Such data may in future refine the ability to define risk of sudden death in a specific patient in 
the future, although they are of limited value at present. Finally, specific single mutations, or 
compound heterozygous states can be associated with a severe clinical phenotype, emphasising 
the importance of genotyping whenever possible.                                                           
            There are several theoretical and practical considerations when implanting an ICD in a 
young population, a detailed description of which is beyond the scope of this review. In general, 
the incidence of inappropriate shocks is high in the paediatric population, related to a variety of 
reasons (sinus tachycardia, supraventricular arrhythmia, nonsustained VT, T wave oversensing 
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or electrode defects). Korte et al demonstrated in a varied population of young patients that there 
were 1.5 appropriate therapies versus 1.3 inappropriate ICD therapies per patient year of follow-
up9. Electrical storms (appropriate shock → emotional distress → sympathetic overdrive → 
more arrhythmias → more shocks) leading to non-acceptance of the device by the patient and 
family have also been reported. Despite the use of various sophisticated ICD algorithms 
(increasing the detection time and rate, use of dual chamber systems with atrial discrimination 
algorithms, detection enhancements such as sudden onset, rate stability, QRS discriminators and 
the use of post-shock high-rate pacing) these problems have not been abolished in LQTS 
patients10.
A role for permanent pacing in LQTS?                                                                         
            The rationale for permanent pacing in the LQTS is that temporary pacing, regardless of 
pacing mode, results in a uniform decrease in QT interval. Pacing also avoids beta-blocker 
induced bradycardia, and protects against pause-dependent torsade de pointes11. Pacing alone 
however is not completely protective12. At present, permanent pacing is confined to neonates and 
infants with severe symptomatic bradyarrhythmia, either sinus bradycardia as seen in LQT1 or 
functional 2:1 AV block as occurs with homozygous LQT2 mutations or an LQT2 mutation in 
association with another mutation13,14. The majority of such patients have QTC>550, and are at 
risk of syncope, haemodynamic compromise and malignant ventricular arrhythmias. High pacing 
rates (100 to 110 beats/min) are usually required for the first 2 years of life, and pacing may be 
considered   a   bridge   to   ICD   implantation.                                                            
The short QT syndrome                                                                                                                   
               This   relatively   recently   recognised   genetic   syndrome   is   uncommon.   The 
electrocardiographic hallmark is a short QT interval of <300ms. It can present at a very young 
age, and carries a high risk of sudden death, syncope and paroxysmal atrial arrhythmias. The 
majority of patients recognised to date have a positive family history of sudden death. 
Electrophysiologically, the SQT is associated with very short atrial and ventricular refractory 
periods. Three disease variants (SQT1 to SQT3) have been identified thus far, and all of them 
are associated with gain of function mutations of one of the cardiac ion channels, resulting in 
abrupt termination of repolarization15-17. When recognised, ICD therapy appears to be uniformly 
indicated, in view of the malignant phenotype. There have been limited data concerning the 
efficacy of quinidine in prolonging and even normalising the QT interval, and in rendering 
ventricular arrhythmia non-inducible18. At present, quinidine may be considered in addition to an 
ICD, to limit the number of ICD discharges.                                                                         
The Brugada syndrome                                                                                                                           
               This   is   an   inherited   arrhythmogenic   disorder   characterised   by   a   typical 
electrocardiographic pattern. It has been linked to mutations in the sodium channel (SCN5A) 
gene, although to date such mutations have been identified in only 20 to 30% of patients with 
definite or suspected Brugada syndrome. The disease is clinically heterogeneous, and has been 
linked to sudden cardiac death in the young, being considered responsible for approximately 
20% of sudden death in patients with structurally normal hearts. The typical symptomatic patient 
however is the young adult male, with a reported mean age at sudden death of around 40 years. 
From predominantly adult studies, the risk factors for sudden death have been identified to be a 
spontaneously occurring type 1 electrocardiogram (particularly in males, although a spontaneous 
type 1 ECG appears to be less common in high-risk female patients) in association with a history 
of syncope or aborted sudden death19,20. The role  of  invasive  electrophysiological  studies  in 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 8(Suppl. 1): S92-S104 (2008)N. Sreeram, U. Trieschmann, E. de Haan, “Device Therapy in Children:                    S95 
Current Indications”
stratifying risk remains controversial; the worse outcome in the Brugada registry for patients 
with inducible ventricular arrhythmia may reflect a selection bias. What is generally agreed upon 
however is that electrophysiologic study has a good negative predictive value - the majority of 
asymptomatic patients who are non-inducible at EPS remain asymptomatic at follow-up21.
           Data in children are derived largely from a single multicenter study of 30 patients (age 
<16 years) from 13 different European centers22. These data confirm what is known from adult 
practice; the majority of symptomatic children had a spontaneously occurring type 1 ECG. There 
was no male preponderance in this population, and family history was unhelpful in predicting 
risk of arryhthmia. The majority of syncopal events occurred during rest, and fever was an 
important trigger of arrhythmic events (syncope or sudden death). The incidence of atrial 
arrhythmias was also higher than has been reported in the adult population. As might be 
expected from such a heterogeneous group, no standardised diagnostic or therapeutic protocols 
were followed. Only a limited number of patients underwent invasive electrophysiologic studies, 
and ICDs were implanted in five children (four of whom had had symptoms). In addition four 
children were treated with quinidine, and none of them (including two who had previously been 
symptomatic) had an arrhythmic event during a limited mean follow-up interval of 28 ± 24 
months. It is not possible on the basis of this report to recommend quinidine as an alternative to 
an ICD in symptomatic patients.                                                                               
            From these and other data, it appears that drug challenge to unmask the typical type 1 
electrocardiographic pattern, while helpful in establishing the diagnosis in individuals with a 
positive family history, does not appear to be useful in identifying patients at risk. In these 
patients, annual follow-up with ECG recording appears to be adequate, to monitor for the 
occurrence of a spontaneous type 1 ECG. In a limited series of children (own unpublished data) 
with a strong family history of sudden death or aborted sudden death, invasive EP studies 
performed in a standardised manner have not thus far been positive in the absence of prior 
symptoms. The indications for ICD implantation concur with those used in adult practice - a 
spontaneous type 1 ECG in association with symptoms. An important caveat is that in patients in 
whom the diagnosis has been established, febrile episodes have to be treated in a timely fashion, 
to avoid fever-related arrhythmic events.                                                                               
Catecholaminergic polymorphic ventricular tachycardia (CPVT)                            
            This syndrome has its onset at a young age. It is characterised by ventricular arrhythmias 
occurring during exercise, when the heart rate typically exceeds a threshold of between 120 and 
130 beats /min. Familial forms account for approximately 30 to 50% of CPVT, with both 
autosomal dominant and recessive forms (ryanodine RyR2 receptor gene and calsequestrin 2 
gene defects) being recognised. This phenotype is associated with a high mortality, with 30 to 
35% of patients with the clinical disease dying before the age of 30 years. In a recent autopsy 
study of young patients dying suddenly, Tester et al identified RyR2 mutations in seven of 49 
individuals (14%) postmortem, suggesting that CPVT may be underdiagnosed in life23.              
            Beta blockers, at a maximally tolerated dose, form the mainstay of therapy. In selected 
patients   with   symptoms   despite   maximal   beta-blocker   therapy,   left   cardiac   sympathetic 
denervation may be helpful in controlling symptoms24. The role of ICDs is controversial. Small 
studies have confirmed the efficacy of ICDs in preventing sudden death25. As for the LQTS, long 
detection times and post-shock pacing / rate-smoothing algorithms will be required to prevent 
excessive shocks and electrical storms.                                                                           
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Arrhythmogenic right ventricular dysplasia (ARVD)                                                                   
            ARVD is a primary cardiomyopathy, which is often familial, and is characterised by 
fibrofatty replacement of the right ventricular myocardium, which in turn can cause sudden 
arrhythmic death in young people. The diagnosis can be difficult, and often requires a 
combination of family history, electrocardiographic abnormalities (depolarisation/repolarisation 
and conduction defects) in association with right ventricular arrhythmias, global or regional right 
ventricular dysfunction and specific histologic changes in the right ventricle.                         
            The indications for ICD implantation in ARVD have been well established from various 
studies in Italy and the mediterranean region, where the disease is most commonly encountered. 
These include a history of aborted sudden death, syncope, sustained ventricular tachycardia 
(with or without haemodynamic compromise), and non-sustained ventricular tachycardia in 
association with a positive family history for sudden death at a young age (<35 years). Slightly 
less well accepted as an indication for ICD is the combination of inducible sustained ventricular 
tachycardia in association with a positive family history of sudden death. When an ICD was 
implanted for one of the above indications, Corrado et al have demonstrated a 15% rate of 
appropriate interventions per year of follow-up26. The incidence of appropriate ICD discharges 
appears to be roughly equal at upto 48 months of follow-up, for each of the above indications, 
and has been shown to be associated with a clear survival benefit26. Concerns remain about lead 
complications at follow-up (undersensing, pacing failure, requirement for additional patches and 
high energy devices), due to the progressive nature of the right ventricular dysplasia. Though 
right ventricular perforation appears to be uncommon, it is not unusual that more right 
ventricular lead positions need to be tested, and that the final R wave amplitude is significantly 
lower compared  to normal hearts26,27.                                                                       
Hypertrophic   Cardiomyopathy                                                                    
               Hypertrophic cardiomyopathy is a progressive primary myocardial disease, whose 
histological hallmarks are myofibrillar disarray and subendocardial ischema/necrosis related to 
the degree of hypertrophy. Several genetic variants of the disease have been recognised. 
Secondary prevention indications for ICD implantation include aborted sudden death and 
documented ventricular tachyarrhythmias with syncope/presyncope28. Much interest has been 
generated in the area of establishing primary prevention indications for ICD implantation in this 
patient population. At present, some of these criteria include a malignant genotype, sudden 
cardiac death in family members, unexplained syncope, abnormal blood pressure response to 
exercise, severe left ventricular hypertrophy with a free wall thickness of the left ventricle in 
excess of 30mm, and induced ventricular tachyarrhythmia or atrial fibrillation29. Follow-up data 
of ICD implantation for secondary prevention show an appropriate annual discharge rate of 
10-11%. When ICDs have been implanted for primary prevention of sudden death, and when 
two or more of the risk factors enumerated above had been present (the European approach), 
there is a 5% per annum incidence of appropriate discharges29. More recently, in selected high 
risk patients, the presence of a single risk factor has been shown to justify justify ICD 
implantation30. In a multi-center study,  Maron et al. demonstrated that appropriate ICD 
discharges occurred in 35% (18/51 patients, in whom monitored risk factors included family 
history   for   sudden   death,   severe   left   ventricular   hypertrophy,   nonsustained   ventricular 
tachycardia on Holter recordings, unexplained syncope) of patients who had undergone ICD 
implantation for a single risk factor. The likelihood of appropriate discharges was also similar 
for patients undergoing primary prevention ICD implant for 1, 2 or 3 or more risk markers30. It is 
likely therefore that ICD use even with one risk marker will gain more widespread acceptance. 
The interval to first appropriate discharge however was upto 10 years, with a 27% probability of 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 8(Suppl. 1): S92-S104 (2008)N. Sreeram, U. Trieschmann, E. de Haan, “Device Therapy in Children:                    S97 
Current Indications”
first   appropriate   discharge   occurring   five   years   or   later   following   ICD   implant.
            There are little data on ICD implantation in children. In a recent publication, Kaski et al 
reported   on   follow-up   data   after   ICD   implantation   in   22   patients   with   hypertrophic 
cardiomyopathy aged <16 years31. Indications for implant included occurrence of a pervious 
cardiac arrest, or the presence of two or more of the previously enumerated risk factors for 
sudden death. Over a short follow-up interval (mean 1.7 years, range 1-2.3 years), the annual 
appropriate ICD discharge.rate was 71.4% for the secondary prevention group, versus 4.1% for 
the primary prevention group. The 5 year shock-free survival rates for secondary prevention 
versus primary prevention were 40% versus 93.3%. Bearing in mind that the risk of sudden 
death in HCM is lifelong, and that intervals to appropriate discharges may be >10 years in 
individual patients, these data do not necessraily detract from the life-saving role of ICDs in this 
patient   population.                                                                
            The left ventricular outflow tract gradient at rest, in the absence of other risk factors, does 
not appear to predict the risk of sudden death32. Further studies need to be undertaken on how 
best to manage patients with a combination of severe outflow obstruction and one or more risk 
factors for sudden death (ICD implantation versus gradient reduction or a combination of the 
two). In addition, transcatheter transcoronary alcohol ablation of septal hypertrophy also does 
not appear to influence the rate of appropriate ICD discharges33.                           
ICDs to Prevent Sudden Death Following Surgical Repair of Structural Heart Defects   
               Population-based studies have established that the cumulative risk of sudden death 
following   surgical   repair   of   congenital   structural   heart   defects   is   low34.   Postoperative 
arrhythmias however are relatively common, and can be an important clinical burden for the 
patient. Patients at risk of sudden death usually have associated chronic pressure or volume 
overload   of   the   ventricle.   In   this   setting,   myocardial   stretch,   ischemia,   fibrosis, 
electromechanical coupling and ventriculo-ventricular interaction may all be causative factors 
for arrhythmia. The observation that the majority of children and young adults with structural 
heart disease are likely to have a ventricular arrhythmia as their presenting arrhythmia during 
cardiac arrest has focused attention on identifying patients at risk of postoperative VT. The four 
categories of lesions that are commonly considered to be associated with a risk of sudden death 
following surgical repair include tetralogy of Fallot, D-transposition of the great arteries 
following a Mustard or Senning repair, congenital aortic stenosis and associated left ventricular 
outflow tract obstruction variants, and palliated univentricular hearts35.                      
               As a general rule, aborted sudden death and recurrent haemodynamically unstable 
polymorphic   ventricular   tachycardia   with   synope/presyncope   would   constitute   definitive 
indications for ICD implantation. Invasive electrophysiological studies have been performed in 
several settings to attempt to identify patients most likely to benefit from an ICD. Alexander et al 
studied 130 patients (mean age 18.7 ± 10.6 years). The patients fell into one of the four disease 
categories enumerated above. Indications for the EP study included symptoms (palpitations, 
syncope), and documented sustained or non-sustained VT. Approximately 14% of patients had 
experienced a near-miss sudden cardiac death event. In this carefully selected population, a 
positive V-STIM study had a high sensitivity (87%), in predicting future mortality. A false 
negative V-STIM outcome however was obtained in upto 33% of the study population. The 
conclusions drawn from the study were that a positive V-STIM identifies a high risk subset of 
patients, while a negative study does not exclude future life-threatening arrhythmic events36. 
Tetralogy   of   Fallot                                                                          
            Sudden cardiac death is the most important cause of mortality after repair of tetralogy of 
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Fallot, with an annual mortality rate of 0.3%35. Risk factors for sudden death include older age at 
repair, a longer duration of follow-up, presence of a right ventricular outflow tract surgical patch, 
high grade ventricular ectopy and early transient heart block37-39. Several electrocardiographic 
markers of sudden death have been identified,  including QRS duration (>180ms, 100% 
sensitivity),   annual  change   of   QRS   duration   (in   msec/year),   and   increased   QT  and   JT 
dispersion40,41. The haemodynamic risk factors associated with ventricular arrhythmia include 
right   ventricular   pressure   and   volume   overload,   and   rather   surprisingly   (and   probably 
underappreciated), left ventricular dysfunction from ventriculo-ventricular interaction38,42,43. The 
combination of QRS duration and the presence or absence of left ventricular dysfunction 
appeared to have the best positive and negative predictive value for sudden death44.          
EP   study   in   tetralogy   of   Fallot                                                                      
            The largest series of patients undergoing EP study following repair of tetralogy of Fallot 
was reported on by Khairy et al45. They studied 252 patients (age 16 ± 12.3 years). Only 25% of 
this patient cohort had had a documented VT or aborted sudden death, and 36% of this 
population were undergoing EP study as part of routine screening. The positive predictive value 
of V-STIM in this rather unselected population was 55%, while the negative predictive valuewas 
91%. The authors reasonably concluded that induction  of monomorphic or polymorphic 
ventricular tachycardia at EPS was predictive of future arrhythmic events. It is important to 
recognise however that a single negative EP study does not provide the patient with a lifelong 
clean bill of health. Issues that need to be studied in the future include recognition of the 
objective criteria for repeating  an EP study,  even when the initial one was negative.  
Surgical repair of residual haemodynamic sequelae                                                                   
            The role of surgical correction of residual haemodynamic sequelae to prevent or cure 
ventricular arrhythmia has also been studied. Therrien et al reported on a series of 70 patients 
who underwent pulmonary valve replacement for chronic pulmonary insufficiency following 
tetralogy repair. Intraoperative cryoablation was performed in 9 patients who had had previous 
ventricular arrhythmias. At follow-up, there was a marked decrease in the incidence of 
ventricular arrhythmias (from 22% to 9%), and none of the patients who had received 
cryoablation had had a recurrence of tachyarrhythmia at a mean follow-up interval of 4.7 years. 
This beneficial effect was however bought at a peri-operative mortality rate of 4%46.     
Ablation/   anti-arrhythmic   medications                                                                    
            Macro-reentrant tachycardia circuits can be successfully ablated (catheter ablation or 
surgery),  and a wide variety of anti-arrhythmic  medications  has been used to suppress 
ventricular ectopy. The role of either of these therapeutic approaches in preventing sudden death 
is   unknown.                                                                          
ICDs   in   tetralogy   of   Fallot                                                                      
            Two recent studies have shed light on the role of ICDs in patients with repaired tetralogy. 
The largest series from North America included 121 patients with a mean age of 32 years, and a 
mean follow-up interval of 3.7 years47. Sixty eight patients (56%) had received an ICD for 
primary prevention, while the remainder (44%) received the ICD for secondary prevention. The 
freedom from appropriate ICD discharges at 1, 2 and 5 years post-ICD implant for primary 
prevention were 85%, 80% and 67% respectively, compared with 79%, 66% and 54% in the 
secondary prevention population. The independent risk factors for appropriate ICD discharge in 
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the secondary prevention population included (not unexpectedly) syncope/presyncope, inducible 
sustained polymorphic ventricular tachycardia, and the use of a class 1A or 1C antiarrhythmic 
drug at hospital discharge. In the primary prevention group, the most important independent 
predictor for appropriate ICD discharge was a higher left ventricular end-diastolic pressure. This 
study emphasises the need to distinguish between appropriate ICD discharges versus potentially 
life-saving discharges in the future, when considering ICD implantation for primary prevention. 
Approximately 33% of patients without previously documented  arrhythmias  had had an 
appropriate ICD discharge within 5 years of device implantation, and it is not clear in how many 
of them the device may have not strictly been indicated. This issue was highlighted by a second 
recent European study48. In this study, 40/64 patients with congenital heart disease undergoing 
ICD implantation (all aged >18 years) had a diagnosis of repaired tetralogy. The index event for 
ICD implantation included cardiac arrest (n=6), spontaneous sustained VT (n=18, predominantly 
monomorphic VT at an average cycle length of approximately 300ms and which was clinically 
well tolerated), syncope (n=11), palpitations (n=1), and various other reasons (n=4). At follow-
up, 160/204 shocks were inappropriate, and 49/64 patients in this cohort experienced an 
inappropriate shock. There were no predictors of inappropriate shocks, except the diagnosis of 
tetralogy of Fallot. A total of 3 possibly life-saving shocks (for polymorphic VT or ventricular 
fibrillation) were documented in the entire tetralogy subgroup, and it was unclear whether all 
these shocks had occurred in the same patient. These data reemphasise the need for stricter 
criteria when implanting an ICD, and on the need to recognise and treat stable and well-tolerated 
VT   by   other   means.                                                                  
Sudden death after the Mustard or Senning procedure for transposition of the great arteries    
            The reported late mortality following atrial repair for D-transposition of the great arteries 
ranges between 3 and 16%. Predictors of late mortality include advanced NYHA functional 
class, pulmonary hypertension and systemic ventricular dysfunction49-51. Sudden death has been 
reported to be the commonest cause of death in several studies49-51. Kammeraad et al studied the 
predictors of sudden death in this patient population52. They identified 47 patients with sudden 
cardiac death or aborted sudden death. Each patient was matched with two controls of a similar 
age, who had undergone the same operation at the same center, within a similar time-frame. The 
mean age at the sudden death event was 12.3 years. Sinus node disease was present in 59%, 
atrial flutter in 42%, a combination of SND and AF in 30%, and permanent pacemakers in 17%. 
The documented rhythm (when available) at the SD event was ventricular tachycardia or 
fibrillation in the majority of patients. The presence of symptoms (of either heart failure or 
arrhythmia) and documented atrial flutter were strong predictors of sudden cardiac death.     
ICDs   following   atrial   repair   of   TGA                                                        
            Secondary prevention indications for ICD implantation are reasonably well agreed upon, 
and include aborted sudden cardiac death and sustained ventricular arrhythmias. The role of 
atrial arrhythmias in causing sudden death is unknown. Khairy et al recently reported on the 
largest cohort of ICD recipients following atrial repair of TGA53. Appropriate ICD discharges at 
follow-up   were   almost   entirely   confined   to   secondary   prevention   patients.   Independent 
predictors of appropriate ICD discharges included moderate or severe systemic AV valve 
regurgitation and the absence of beta blocker therapy. In conjunction with the findings of the 
Kammeraad study where documented atrial arrhythmias predicted sudden death, it may be 
speculated that beta blockers may have had a role in suppressing atrial arrhythmias in this patient 
population.   Interesting   issues   which   require   further   consideration   and   study  include   the 
following: (1). Should patients with documented atrial flutter routinely undergo a V-STIM 
study? (2). At the time of a routine pacemaker revision, should a V-STIM study be performed, to 
make the decision to upgrade to an ICD?                                                               
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Conclusions
               The optimal treatment for preventing sudden death in post-surgical patients with 
congenital heart disease is likely to involve a hybrid approach, using a combination of 
haemodynamic   repair,   surgical   or   catheter   ablation   of   macro-reentrant   ventricular 
tachyarrhythmias, catheter ablation or pharmacologic therapy for atrial arrhythmias, and ICD 
implantation.   Risk  assessment   in   ths  patient   population   remains   challenging   due  to   the 
heterogeneity   of   structural   heart   diseases,   the   unpredictable   progression   of   adverse 
haemodynamic sequelae and their effect on ventricular function, the unpredictable timing of 
clinical events, and not least the low annual mortality rates. 
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